Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

Journal:
Blood
Published:
Affiliations:
2
Authors:
3
Institutions Authors Share
The George Washington University (GW), United States of America (USA)
2.000000
0.67
Georgetown University Medical Center (GUMC), United States of America (USA)
1.000000
0.33